Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Question for the day traders : approaching market open, when the bid is greater than previous day's close, does that necessarily signal an upward trend for the current day?
I'm very sceptical about a verb connection for anything beyond software which seems to be all the Verb machine is made of at the moment(which would be a amazing connection already though).
But for what is worth, and this a little strange, when I once typed TITXF in the finance search engine of yahoo, for some strange reason it gave me the GOOGL page. So since then, it's been difficult for me to shake the connection...
Yep...strange...and blame one a glass of wine too many that evening if you like...I do...sorta...
In time, we'll talk about it over a Scotch instead...or not..
What I'd like an explanation for, however, if there is a connection, why keep it under wraps, and why not make it public?
Sport is the Egg Verb is the Chicken, and yes the egg came before the chicken
https://titanmedicalinc.com/investors/agm-information/
2015 agm conference 28 minutes amd 47 seconds Hargrove says ..."we have the advantage of working with strategic partners....
then he pauses ....
takes his glasses down & makes sure to make eye contact with everyone in the room left to right and with a confident and loud
"MORE TO COME ON THAT"
Fowler then comes out and speaks about the same principles Verb has been touting in all their press releases a year later
Sport fits in a elevator...listen to Hargrove 28:46 seconds AGM conference call
http://www.titanmedicalinc.com/investor-relations/sport-clips/
Nah this is old. They had something pop up about a mobile cart that can fit into an elevator.
I saw that and asked around since I haven’t seen a disclosure where he lists ISRG. his payments for isrg are education, which could be a fellowship program or being a proctor. The fellowship program makes sense since the payments lineup right after when the courses were held. This is way different than product development.
https://globenewswire.com/news-release/2016/05/25/843260/0/en/Intuitive-Surgical-Announces-Support-for-2016-Gynecology-Fellowship-Programs.html
ISRG paid Advincula $51,500 in 2016 all the while he was on Titans advisory board.
Exactly. They have nothing to show of their own. They show investors. What investors do they need? We are talking about two of the biggest companies on the planet. This is all hocus pocus and a diversion, IMO
JnJ Google getting ready to launch SPORT!
WTF?????? LOL!!!!!
This is my point. It’s very possible. It’s very very unlikely to have robotic surgeons working in two different platforms as consultants. It’s just not legally possible. Eduardo parra-Davila and vip Patel have been top ethicon consultants for a while. Just makes no sense to me.
I guess they must be launching SPORT. What else could it be?
BTW Verb doesn't need to raise money so they don't have to show anything. Why would they?
"Launch Excellence Process" ?? Ethicon dose not have any substantial patents that have ever been dug up and neither does SRI... what are they Launching??
At least show the investor a CAD drawing like EVERY OTHER COMPANY.
Even Senhance had a CAD drawing!
I've posted plenty of detail in the past. It's all out there if you want to do some real DD.
There was a job posting for JnJ in the summer that I thought was very interesting. It was for a director of M&A with a background in robotics and would be working closely with Verb. It does make a lot of sense for a company like Verb to partner with Titan. We will own single port surgery.
They should want to be part of that revolution....
Same ol song and dance. Talking about Ethicons patents WITHOUT any detail.
I’m actually in the camp that believes there is no connection, but there are so many coincidences and the list grows weekly. Sport and Orep, look up recent ethicon job postings for marketing positions for this endeavor.
J&J is now calling it the “Launch Excellence Process”. Titan aptly names their clinical sites “Centers of Excellence”. Hardly a match but the language continues to run parallel.
I think we have a shot at being one of many robots on a very robust Verb platform.
This topic has been beaten to death. We don't agree on this one.
If you find new evidence of a collaboration please share. Would love for you to be right.
I'm not making any claim...Ive stood by that its a possibility. Thats all. Rocko said its 100%...not me. You say NO WAY...I don't agree with you. Sorry...
Ive talked about the consultants overlapping...working with Nicholson, which is ethicons hub...dumping SAIL, which is covidiens hub...Huennekens being INVITED in to see the robot in a private showing??? WHo does that? Come ST...
What patents of significance though? Ive seen old a$$ patents and nothing that suggests they have a viable robot. others have looked hi and low as well. Ethicons patents revolve around........ready??? End effectors and the devices...You keep pushing this yet do not show anything to support what you say. I mean...SRI has a patent for a bomb robot...
You know that there are dozens of patents for Ethicon and SRI. Why do you insist there aren't any?
Show us just one piece of evidence that we are a collaboration partner. Your the one who is all but making that claim.
You prove it.
So wait...if you cant prove it...and you cant provide the info that I'm requesting/questioning...then you cant definitively say that one of those collaboration partners isn't Titan?
I agree and look forward to that announcement! Trust me I would LOVE to see it. I do believe there is a good chance we partner with them or another company.
That would be Freakin the Sheet Great
I can't prove it. I also can't prove there isn't a Santa Clause. Believe what you want but the fact is there are plenty of surgical robotic patents by Ethicon and SRI. Ethicon has the most robotic patents after ISRG. They are easy to find and longtime readers here know that.
Does Ethicon have a patent for a patient cart? No.
Does Titan? No.
These companies have patents for elements of their design and function.
Ethicon has dozens of them. Also have an army of robotic engineers.
I guess we have to revisit this from time to time. I don't get it.
Maybe we partner with Verb soon. That would be great.
I am BUFFALO BILLiever in the Rocko Verb/Ethicon/Titan theory
How can you be sure ST???
These articles are old. Dec 2016
Jan 2017.
Titan is not collaborating with Verb.
Its funny how the collaboration went from just being google and JNJ to other partners now...anyone find any work station/controller/patient cart patents yet???? I still cant find a single one...
COLLABORATION PARTNERS robotics, visualization, advanced instrumentation, data analytics, and connectivity – developed by Verb and its collaboration partners
Rocko Rocko mannnnnn I want to be a Rockooo man... Rocko Rocko mannnnn, I want to be a Rocko Verb man
Verb Surgical Delivers Digital Surgery Prototype Demonstration to Collaboration Partners
Mountain View, CA – January 26, 2017. Verb Surgical Inc. announced today that the company has demonstrated its first digital surgery prototype to its collaboration partners at Ethicon Endo-Surgery, Inc., part of the Johnson & Johnson Medical Devices Companies, and Verily Life Sciences (formerly Google Life Sciences), as well as senior leadership from Johnson & Johnson and Alphabet Inc.
The digital surgery platform included all elements of the company’s five technology pillars – robotics, visualization, advanced instrumentation, data analytics, and connectivity – developed by Verb and its collaboration partners.
The latest demonstration was attended by executives from Ethicon, Verily, Johnson & Johnson and Alphabet, including Alex Gorsky, Chairman & CEO of Johnson and Johnson, and Sergey Brin, co-founder of Alphabet, Inc. and Google.
“This is a tremendous achievement for Verb and our collaboration partners at Ethicon, and Verily,” said Verb Surgical CEO Scott Huennekens.
“Verb is a company driven by taking action for surgeons and patients. Completing this prototype milestone was an achievement that we aimed for a year ago, and I’m excited to say we achieved it and are on track with our development schedule to deliver Surgery 4.0 with our platform,” continued Huennekens.
"The team has made important progress since Verb was formed in August 2015. The digitally-enabled surgery platform is a great example of how healthcare can be transformed through innovation," said Gary Pruden, Executive Vice President and Worldwide Chairman, Medical Devices, Johnson & Johnson.
Sergey Brin stated, "It is extremely exciting to see the hard work Verily has been doing in optics, electronics, software, and more to take the next big step toward saving lives. Thanks to all of our partners and collaborators at Johnson & Johnson, Verb, and others."
Scott Huennekens further noted that Verb has been demonstrating the working prototype to its stakeholders for the past several months. “Verb is in a very unique position to leverage technology in ways never imagined before,” said Huennekens, “and we’ve just taken one major step forward to creating the future of surgery.”
I also think that getting systems into the latter two locations will be much quicker and simpler that at Nicholson by virtue of the fact that they now have already done it, plus they know what other prep work needs to happen, and some training materials, fixtures, etc. are already developed by Nicholson. The two subsequent installations should be pretty much a slam dunk. I would not be surprised if folks from those two locations have already been through some training at Nicholson on the SPORT device so they can dive right in when the hardware arrives at their respective site.
With some of the recent comments made by McNally. I get the feeling they are ahead of schedule in multiple facets of SPORT but are keeping it to themselves. But with the Nicholson announcement he made it a point to slip in there "ahead of our 4th quarter timeline". That comment, though subtle, spoke volumes, IMO.
it took just over two months to deliver sport to nicholson after announcement of this site. if the same timeline; i figure delivery to strasbourg aroud 10/30/17 and columbia around 12/4/17. that said who knows they may already be there.
Keep in mind we have two more sites that SPORT has just been installed, or will be shortly (within Q4). Surgeon feedback, reviews, are scheduled this quarter before year end. After the VERY positive, glowing remarks from 3 renowned surgeons at the first site (Nicholson), what are the chances the 2nd and 3rd site surgeons will have a different/critical take?? I'm guessing slim to none. I can't see Patel and company getting it that wrong.
With that said, it's nice to have some forthcoming (almost certainly) positive SPORT reviews up are sleeve. Hence, my view we end up at .50+ by year end. Sure dilutive financing could temporarily derail this, but I believe they are holding out on this until after the 2nd and 3rd site feedback/reviews. They want as much pop as they can get before going back to the well...JMHO
GLTA
I will clear this up. The reason for the discrepancy yesterday was there was a trade that went through just seconds after the close at .238, but the stock closed at .228, this the flip flop back and forth depending on your brokerage firms software showing the current price or closing price. Either way, we are headed higher boys and girls, let's go!
You guys are freaking over tenths of a cent on a 20 cent stock that you reasonably expect to be worth 5 to 100 dollars in a couple years........... relax ............. plenty to worry about with Titan besides that.
Moving on up! Perhaps all that was needed was a few days for the stock to catch its breath... If so, we are headed into the 30s I would think, especially if we can get a spark with another exciting PR soon.
I do appreciate the added detail for clarification!
I also recall a couple companies breaking into a new technology 15 years ago... I guess these lawsuits do have precedents, although the end result was staggering success!
http://surgrob.blogspot.com/2010/03/vintage-report-on-intuitive-vs-computer.html
We also all knew this surge up would stop and we'd see a dip downwards. We had several of our "board experts" people say so. So it was predicted and expected. Yet even though we knew this, expected this and discussed it. We still had people flipping out. I don't think some here fully realize that Titan now has a legitimately WORKING ROBOT that is getting rave reviews from some of the top surgeons. We are on the verge of putting a working, FDA approved surgical robot on the market. The feedback from Nicholson should have put a lot of worry and concerns that we normally had behind us. We're almost there.
Mustang
I have the greatest respect for your posts, and have stated so in the past, you are one of the few here who states the facts as you see them with decorum, and class, no name calling or degrading.
I did not flip at all, I stated in the past that I was concerned about patent infringement, I am not saying we are infringing on any patents, what I am saying is that filing a lawsuit is a common way large corporations tie up and stall little guys from getting to full production and sales. As with many lawsuits, it does not have to be valid to be troublesome. I believe we have a great product, and patents to back it up, but that does not mean you cannot be tied up in court for extended periods proving it, and that is if you win at all. Having the most and best lawyers not the best case is often enough to win. Believe me I pray I am totally wrong.
After what we just saw happen, it doesn’t matter. There’s an amazing impetus for this stock to fire up on significant news. News that is surely coming. I, for one, am sitting like a vulture on a limb waiting for another good entry point.
I noticed the same glitch. At 4:30, TD showed the close at 0.2380, but my gain/loss for the day didn't jive with that number. An hour later the close reset to 0.2280. Weird.
So, what happened to "award-winning IP" at Titan? We went from having the best IP protection around and getting through an intense IP review just a few months ago to "Hey, we'll probably get sued for patent infringement!"
Might I suggest a career in politics for the flip-floppers out there? I'm sticking with Mr. Brar and the "IP is sewn up tight" story.
Those numbers happen to be (maybe coincidence, maybe software glitch) the current Bid (.223) and Ask (.238).
Titan Medical
January 10, 2022 Titan Medical Corporate Presentation
https://d1io3yog0oux5.cloudfront.net/_101e2d94c73b26bc133246c537736f29/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+Q1+2022+FINAL.pdf
*200+ patents issued or pending
Surgeon Feedback From Initial Clinical Testing:
Ricardo Estape, M.D., a robotic gynecologic oncology surgeon from South Miami Gynecology Oncology Group who specializes in robotic single port surgeries, said, “The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.” SEE VIDEO
Eduardo Parra-Davila, M.D., a robotic colorectal surgeon at Florida Hospital who has trained thousands of surgeons worldwide on robotic surgery, commented, “Single port surgery without robotic assistance is not easy and yet it remains highly beneficial because of the desire to have fewer ports. It’s all about robotic articulation delivered through a single incision that allows for the reach, necessary angles and multi-quadrant access to treat diseases in colorectal surgeries. The SPORT Surgical System has the promise to become a valuable tool for all robotic surgeons looking to do single port surgery in the future.” SEE VIDEO
Arnold Advincula, M.D., Chief of Gynecologic Specialty Surgery at Columbia University and an expert in robotic surgery, said, “After using the SPORT system, I am more convinced that single-port robotic surgery could become a reality for many patients. Previous approaches to single-incision surgery have been limiting and ineffective. The SPORT system demonstrated that it can not only address those limitations, but it may also provide some unique capabilities for enabling a variety of gynecologic surgeries through a single incision. The future of single-port robotic surgery is bright and I am excited to actively participate in this journey with Titan Medical.”
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
William Burke, M.D., a gynecologic oncologist at Stony Brook University Hospital with extensive robotic surgery experience, commented, “Having completed thousands of multi-port robotic surgeries over several years of practice, I was pleased with the capabilities of the SPORT system that eased my transition from a multi-port approach to single-port robotic surgery. The workspace, access and ease of use while maintaining critical multi-port robotic features such as multi-articulated instruments and high-definition 3D visualization through a single incision, are important factors in transitioning from multi-port to single-port robotic surgery. I must say that the SPORT system, with its sophistication, makes a highly compelling case for single-port robotic surgery.”
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
Jelle Ruurda, MD, a gastrointestinal and oncologic surgeon at University Medical Center Utrecht, who has several years of robotic surgery experience, commented, “Many oncologic general surgery procedures require specimen retrieval at the end of the procedure. These procedures are natural applications for single-port robotic surgery. My first operation of the SPORT system in a preclinical environment was very exciting, and the system shows great promise for future clinical use. I look forward to the opportunity to work together with Titan Medical to evolve a single-port robotic surgery option for my oncology patients. Based on this first experience, I am confident that single-port robotic surgery has a bright future”.
Eric Barret, MD, a world-renowned robotic urologic surgeon at Institut Mutualiste Montsouris, said, “Having performed many single-incision robotic surgeries with flexible, non-wristed and crossed-over instruments, my first experience with the SPORT system was exceptional. The SPORT system addresses many limitations of previous laparoscopic and robotic single-incision surgery approaches, and holds significant promise for meaningful use in urologic applications.”
The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation. http://www.titanmedicalinc.com/
Interim President & CEO
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility. Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors. He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.
Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.
Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.
Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.
Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |